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The Underrecognized Role of Impaired Muscle Function in 
Cancer-Related Fatigue 
By Alexander V. Ng 
 
This timely article by Drs. Davis and Walsh provides a succinct overview of the 
task-dependent mechanisms that could limit neuromuscular function to result in increased 
muscle fatigue or decreased muscle endurance. This work has particular importance to cancer 
survivorship, because such mechanisms could possibly explain part (or all) of the phenomenon 
of cancer-related fatigue (CRF). Anemia, cachexia, and malnutrition are well-understood 
consequences of cancer or its treatment that can contribute to CRF, but impaired neuromuscular 
or muscle function resulting in muscle fatigue has attracted comparatively little attention. This 
finding is somewhat surprising given that the process (decreased maximal force generation) or 
consequences (eg, decreased endurance) are readily quantifiable using the standard techniques 
highlighted by Drs. Davis and Walsh. 
From a broad perspective, an understanding of muscle or neuromuscular fatigue could 
provide a mechanistic link that is somewhat lacking in some current models of CRF. For example, 
it is becoming increasingly accepted that exercise is one of the few effective tools for managing 
unexplained CRF in the absence of anemia or cachexia. The mechanism of action of exercise 
could be through preserving muscle strength or endurance by preventing deterioration of 
function or by enhancing it.1 This process could be particularly important in the case of peripheral 
fatigue secondary to disuse, whereby exercise could be thought of as a countermeasure to 
disuse. Of course, exercise could also exert a beneficial central effect on altered mood such as 
depression, which is a common correlate to fatigue. 
Another possible mechanistic role for muscle in CRF that has not been fully explored 
centers on the relationship between proinflammatory cytokines and fatigue not explained by 
cachexia or anemia. In some cancers and treatments, proinflammatory cytokines are clearly 
becoming players, although the mechanisms have not been fully elucidated.2 In the case of 
cytokine-mediated fatigue, inflammatory cytokines could have an end-tissue result that could 
reside in the mitochondria of muscle and manifest as a decrease in muscle endurance, or an 
increase in fatigability. Production of proinflammatory cytokines could occur from cancer or its 
treatment and exert a systemic effect some distance from the site of origin. Certainly, any role for 
impaired oxidative mitochondrial processes could be elucidated with 31P magnetic resonance 
spectroscopy, as suggested by Drs. Davis and Walsh.  
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The authors make a case for CNS involvement in the fatigue of various chronic diseases 
including cancer. The implications for CNS impairment are far-reaching in cancer survivorship. 
For example, in many patients with breast cancer undergoing chemotherapy, the so-called 
chemobrain phenomena can be manifest as impaired cognition. This implies a 
chemotherapy-induced central alteration, which might be paralleled by impaired central 
activation to muscle contraction. Drs. Davis and Walsh emphasize the utility of transcranial 
magnetic stimulation (TMS), which, along with other electromyographic techniques, could help 
elucidate whether central motor impairment occurs in this population as well as test other 
intriguing and clinically relevant questions. Indeed, our own initial observations using TMS 
suggest a supraspinal role for decreased muscle endurance, albeit in a single survivor of breast 
cancer.3 
Although the authors present a strong and valid argument for centrally mediated fatigue 
in cancer survivors, including their own excellent work, a potential contribution from peripheral 
factors should not be neglected. Bruera and colleagues showed evidence for peripherally 
mediated muscle fatigue during electrically stimulated contractions in women with advanced 
breast cancer.4 In our own preliminary work with survivors of prostate cancer undergoing 
radiotherapy, we observed decreased endurance consistent with mitochondrial oxidative 
impairment with no central impairment.5 However, a possibly centrally mediated decrease in 
neuromuscular efficiency has also been reported in this population.6 Interestingly, despite this 
decreased neuromuscular efficiency, at rest and during exercise, the rate of muscle fatigue per 
se was not affected.6  
 
The Clinical Relevance of Both Muscle Fatigue and CRF 
Fatigue has different meanings to different people and disciplines. As we begin to 
understand more about fatigue, it becomes important to differentiate, to the best of our abilities, 
exactly what domain of fatigue we refer to. The protean nature of the fatigue construct was 
acknowledged by the authors, yet the current review presents a clear overview primarily of 
muscle or neuromuscular fatigue. The overriding question then becomes to what extent can 
muscle or neuromuscular fatigue explain the symptoms of cancer-related fatigue. In the case of 
multiple sclerosis, an autoimmune disease, symptomatic fatigue and muscle fatigue can be 
independent.7,8 This last point suggests that although an understanding of neuromuscular 
processes may be critical to comprehending CRF, muscle fatigue and CRF may also be two 
independent entities. However, even if this is the case, it would not by any means imply that 
muscle, or physiologic, fatigue is unimportant to oncologists, because both CRF and muscle 
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fatigue are both clinically relevant in their own right. Finally, because CRF is most often reported 
as subjective fatigue (quantified by survey or questionnaire), use of a multidimensional survey 
instrument, with a subscale that might be sensitive to muscle or neuromuscular fatigue, could 
help to promote a greater understanding between muscle fatigue and CRF. 
Drs. Davis and Walsh have presented a clear overview of muscle fatigue and the 
techniques to study it in health and disease. Their work will help to promote a greater 
appreciation of the role that muscle fatigue may play in the sometimes debilitating CRF so often 
experienced by cancer survivors before, during, or after treatment. In addition, their overview 
should stimulate research in an area that, despite recent attention, remains in its infancy. Only 
when there exists a clear understanding of CRF, including muscle fatigue, can optimal 
therapeutic interventions be developed. 
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